Coronary artery disease in patients with cystic fibrosis – A case series and review of the literature
暂无分享,去创建一个
A. Moran | J. Wyckoff | M. Putman | A. Moheet | Noura Nachawi | Zahrae Sandouk | S. Soltman | S. Kiel | R. Simon
[1] Rizwan Kalani,et al. Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association , 2022, Circulation.
[2] D. Kirk,et al. Acute ST-elevation myocardial infarction in two young women with cystic fibrosis and cystic fibrosis-related diabetes , 2021, Journal of Cystic Fibrosis.
[3] A. Thiagalingam,et al. Azithromycin and tezacaftor/ivacaftor is associated with first-degree heart block in an adult with cystic fibrosis. , 2020, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[4] A. Moran,et al. Prevalence and factors associated with overweight and obesity in adults with cystic fibrosis: A single-center analysis. , 2019, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[5] C. Teneback,et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial , 2019, The Lancet.
[6] L. Lands,et al. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. , 2019, The New England journal of medicine.
[7] B. Quon,et al. Safety and effectiveness of lumacaftor-ivacaftor in adults with cystic fibrosis: A single-center Canadian experience , 2019, Canadian Journal of Respiratory, Critical Care, and Sleep Medicine.
[8] C. Goss,et al. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. , 2017, The Lancet. Respiratory medicine.
[9] R. Levy,et al. Coronary artery disease in cystic fibrosis: An emerging concern? , 2016, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[10] S. Somerset,et al. Dietary intake and nutritional status of micronutrients in adults with cystic fibrosis in relation to current recommendations. , 2016, Clinical nutrition.
[11] Xiaohong Huang,et al. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. , 2015, The New England journal of medicine.
[12] K. Dwan,et al. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis. , 2015, The Cochrane database of systematic reviews.
[13] A. Moran,et al. Diabetes-related mortality in adults with cystic fibrosis. Role of genotype and sex. , 2015, American journal of respiratory and critical care medicine.
[14] B. Morrissey,et al. Inflammation, oxidative stress, and cardiovascular disease risk factors in adults with cystic fibrosis. , 2014, Free radical biology & medicine.
[15] 刘欣,et al. Clinical care guidelines for cystic fibrosis-related diabetes:a position statement of the Americal Diabetess Association and a clinical practice guideline of the Cystic Fibrosis Foundation ,endorsed by the pedistric Endocrine Society , 2011 .
[16] K. Robinson,et al. Clinical Care Guidelines for Cystic Fibrosis–Related Diabetes , 2010, Diabetes Care.
[17] F. Perrin,et al. Ischaemic heart disease - a new issue in cystic fibrosis? , 2010, Journal of the Royal Society of Medicine.
[18] G. Onady,et al. An adult cystic fibrosis patient presenting with persistent dyspnea: case report , 2006, BMC pulmonary medicine.
[19] R. Heine,et al. Clinical significance of the physicochemical properties of LDL in type 2 diabetes , 2005, Diabetologia.
[20] E. Parks,et al. Abnormal lipid concentrations in cystic fibrosis. , 2002, The American journal of clinical nutrition.
[21] K. Webb,et al. The heart in cystic fibrosis. , 2002, Journal of the Royal Society of Medicine.
[22] S. Bell,et al. Microvascular complications in cystic fibrosis-related diabetes mellitus: a case report. , 2000, JOP : Journal of the pancreas.
[23] Daniel Levy,et al. Lifetime risk of developing coronary heart disease , 1999, The Lancet.
[24] J. Gustafson,et al. Cystic Fibrosis , 2009, Journal of the Iowa Medical Society.